Ipamorelin vs HGH 191AA
Head-to-head comparison of Ipamorelin and HGH 191AA for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ipamorelin | Hgh 191aa |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. | HGH 191AA binds to the growth hormone receptor (GHR) on target cells, triggering JAK2-STAT5 signaling, which drives transcription of IGF-1 and other growth factors. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (multiple indications). Numerous brand-name products available worldwide. |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Common: injection site reactions, fluid retention, joint pain/stiffness, carpal tunnel syndrome; Metabolic: insulin resistance, hyperglycemia (dose-dependent), may precipitate diabetes |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 0.15-2 mg per injection (0.5-6 IU) |
| Frequency | 2–3 times daily (typically before meals and before bed) | Once daily |
| Molecular Weight | ~711.9 g/mol | ~22,124 g/mol |
| Half-Life | ~2 hours | ~3-5 hours (SC) |
Overview
Ipamorelin and HGH 191AA are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
BPC-157 5mg
5mg
HGH 191AA — Mechanism & Evidence
HGH 191AA refers to recombinant human growth hormone (somatropin) — a 191-amino acid, single-chain polypeptide (MW ~22,124 g/mol) identical in sequence to endogenous pituitary growth hormone. In the peptide community, "191AA" distinguishes legitimate somatropin from the older 192-amino acid variant (somatrem, which had an extra methionine and higher immunogenicity).
Key claims: Treats growth hormone deficiency; Improves body composition in GH-deficient adults; Anti-aging and rejuvenation effects in healthy elderly.
Shared Research Applications
Both peptides are studied for: Body Composition.
Ipamorelin is also researched for: Anti-Aging, Sleep.
HGH 191AA is also researched for: Anti-Aging & Longevity.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
HGH 191AA: Common: injection site reactions, fluid retention, joint pain/stiffness, carpal tunnel syndrome Metabolic: insulin resistance, hyperglycemia (dose-dependent), may precipitate diabetes Endocrine: gynecomastia, hypothyroidism (may unmask central hypothyroidism)
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe